SLXN - Silexion Therapeutics Corp
1
-0.080 -8.000%
Share volume: 42,533
Last Updated: 04-21-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
0.21%
PREVIOUS CLOSE
CHG
CHG%
$1.08
-0.08
-0.07%
View ratios
| Fiscal Date | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 08-29-2024 | 11-14-2024 | 03-18-2025 | 05-13-2025 | 11-12-2025 | 03-17-2026 | |
| Total revenue | -102.000 K | -3.822 M | 0.000 | -85.000 K | 30.000 K | 55.000 K | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | -102.000 K | -3.822 M | 0.000 | -85.000 K | 30.000 K | 55.000 K | |
| -3,647.06% | 100.00% | 135.29% | 83.33% | ||||
| Operating expenses | 1.385 M | 8.036 M | 0.000 | 1.650 M | 3.292 M | 4.406 M | |
| Selling general and admin | 619.000 K | 4.819 M | 0.000 | 1.060 M | 1.135 M | 1.031 M | |
| Research and development | 766.000 K | 3.217 M | 0.000 | 590.000 K | 2.157 M | 3.375 M | |
| Total expenses | 1.385 M | 8.036 M | 0.000 | 1.650 M | 3.292 M | 4.406 M | |
| 480.22% | -100.00% | 99.52% | 33.84% | ||||
| Operating income | -1.385 M | -8.036 M | 0.000 | -1.735 M | -3.292 M | -4.321 M | |
| Ebit | -1.385 M | -8.036 M | 0.000 | -1.735 M | -3.292 M | -4.321 M | |
| Pretax income | -1.487 M | -11.858 M | 0.000 | -1.735 M | -3.262 M | -4.412 M | |
| 697.44% | -100.00% | 88.01% | 35.25% | ||||
| Income tax | 2.000 K | 2.000 K | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -1.489 M | -11.860 M | 0.000 | -1.735 M | -3.262 M | -4.412 M | |
| -696.51% | 100.00% | -88.01% | -35.25% |